GLP-1 receptor agonists are associated with risk reductions for dozens of diseases and conditions in addition to rapid weight ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly's weight loss pill doesn’t appear to work as well as Wall Street had hoped. The drugmaker said Thursday the highest ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

An oral GLP-1 induced up to 12.4% weight loss at 72 weeks for adults with overweight or obesity, according to topline results ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Eli Lilly (LLY) reported better-than-expected earnings for the second quarter on Thursday. But disappointing results of its ...